PMID- 33633310
OWN - NLM
STAT- MEDLINE
DCOM- 20211220
LR  - 20211220
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 11
IP  - 1
DP  - 2021 Feb 25
TI  - Clinical difference between fibroblast growth factor receptor 2 subclass, type 
      IIIb and type IIIc, in gastric cancer.
PG  - 4698
LID - 10.1038/s41598-021-84107-x [doi]
LID - 4698
AB  - Fibroblast growth factor receptor 2 (FGFR2) has two isoforms: IIIb type and IIIc 
      type. Clinicopathologic significance of these two FGFR2 subtypes in gastric 
      cancer remains to be known. This study aimed to clarify the clinicopathologic 
      difference of FGFR2IIIb and/or FGFR2IIIc overexpression. A total of 562 patients 
      who underwent gastrectomy was enrolled. The expressions of FGFR2IIIb and 
      FGFR2IIIc were retrospectively examined by immunohistochemistry or fluorescence 
      in situ hybridization (FISH) using the 562 gastric tumors. We evaluated the 
      correlation between clinicopathologic features and FGFR2IIIb overexpression 
      and/or FGFR2IIIc overexpression in gastric cancer. FGFR2IIIb overexpression was 
      observed in 28 cases (4.9%), and FGFR2IIIc overexpression was observed in four 
      cases (0.7%). All four FGFR2IIIc cases were also positive for FGFR2IIIb, but not 
      in the same cancer cells. FGFR2IIIb and/or FGFR2IIIc overexpression was 
      significantly correlated with lymph node metastasis and clinical stage. Both 
      FGFR2IIIb and FGFR2IIIc were significantly associated with poor overall survival. 
      A multivariate analysis showed that FGFR2IIIc expression was significantly 
      correlated with overall survival. FISH analysis indicated that FGFR2 
      amplification was correlated with FGFR2IIIb and/or FGFR2IIIc overexpression. 
      These findings suggested that gastric tumor overexpressed FGFR2IIIc and/or 
      FGFR2IIIb at the frequency of 4.9%. FGFR2IIIc overexpression might be independent 
      prognostic factor for patients with gastric cancer.
FAU - Yashiro, Masakazu
AU  - Yashiro M
AD  - Molecular Oncology and Therapeutics, Osaka City University Graduate School of 
      Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan. 
      m9312510@med.osaka-cu.ac.jp.
AD  - Department of Gastroenterological Surgery, Osaka City University Graduate School 
      of Medicine, Osaka, Japan. m9312510@med.osaka-cu.ac.jp.
AD  - Cancer Center for Translational Research, Osaka City University Graduate School 
      of Medicine, Osaka, Japan. m9312510@med.osaka-cu.ac.jp.
FAU - Kuroda, Kenji
AU  - Kuroda K
AD  - Molecular Oncology and Therapeutics, Osaka City University Graduate School of 
      Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan.
AD  - Department of Gastroenterological Surgery, Osaka City University Graduate School 
      of Medicine, Osaka, Japan.
FAU - Masuda, Go
AU  - Masuda G
AD  - Molecular Oncology and Therapeutics, Osaka City University Graduate School of 
      Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan.
AD  - Department of Gastroenterological Surgery, Osaka City University Graduate School 
      of Medicine, Osaka, Japan.
FAU - Okuno, Tomohisa
AU  - Okuno T
AD  - Molecular Oncology and Therapeutics, Osaka City University Graduate School of 
      Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan.
AD  - Department of Gastroenterological Surgery, Osaka City University Graduate School 
      of Medicine, Osaka, Japan.
FAU - Miki, Yuichiro
AU  - Miki Y
AD  - Molecular Oncology and Therapeutics, Osaka City University Graduate School of 
      Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan.
AD  - Department of Gastroenterological Surgery, Osaka City University Graduate School 
      of Medicine, Osaka, Japan.
FAU - Yamamoto, Yurie
AU  - Yamamoto Y
AD  - Molecular Oncology and Therapeutics, Osaka City University Graduate School of 
      Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan.
FAU - Sera, Tomohiro
AU  - Sera T
AD  - Molecular Oncology and Therapeutics, Osaka City University Graduate School of 
      Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan.
AD  - Department of Gastroenterological Surgery, Osaka City University Graduate School 
      of Medicine, Osaka, Japan.
FAU - Sugimoto, Atsushi
AU  - Sugimoto A
AD  - Molecular Oncology and Therapeutics, Osaka City University Graduate School of 
      Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan.
AD  - Department of Gastroenterological Surgery, Osaka City University Graduate School 
      of Medicine, Osaka, Japan.
FAU - Kushiyama, Shuhei
AU  - Kushiyama S
AD  - Molecular Oncology and Therapeutics, Osaka City University Graduate School of 
      Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan.
AD  - Department of Gastroenterological Surgery, Osaka City University Graduate School 
      of Medicine, Osaka, Japan.
FAU - Nishimura, Sadaaki
AU  - Nishimura S
AD  - Molecular Oncology and Therapeutics, Osaka City University Graduate School of 
      Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan.
AD  - Department of Gastroenterological Surgery, Osaka City University Graduate School 
      of Medicine, Osaka, Japan.
FAU - Togano, Shingo
AU  - Togano S
AD  - Molecular Oncology and Therapeutics, Osaka City University Graduate School of 
      Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan.
AD  - Department of Gastroenterological Surgery, Osaka City University Graduate School 
      of Medicine, Osaka, Japan.
FAU - Ohira, Masaichi
AU  - Ohira M
AD  - Department of Gastroenterological Surgery, Osaka City University Graduate School 
      of Medicine, Osaka, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210225
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - EC 2.7.10.1 (FGFR2 protein, human)
RN  - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 2)
SB  - IM
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lymph Nodes/metabolism
MH  - Prognosis
MH  - Receptor, Fibroblast Growth Factor, Type 2/classification/*metabolism
MH  - Retrospective Studies
MH  - Stomach Neoplasms/*metabolism/pathology
MH  - Survival Rate
PMC - PMC7907198
COIS- Masakazu Yashiro received research funding from Daiichi Sankyo Co., Ltd. The 
      other authors declare no competing interests.
EDAT- 2021/02/27 06:00
MHDA- 2021/12/21 06:00
PMCR- 2021/02/25
CRDT- 2021/02/26 05:59
PHST- 2020/09/27 00:00 [received]
PHST- 2021/02/08 00:00 [accepted]
PHST- 2021/02/26 05:59 [entrez]
PHST- 2021/02/27 06:00 [pubmed]
PHST- 2021/12/21 06:00 [medline]
PHST- 2021/02/25 00:00 [pmc-release]
AID - 10.1038/s41598-021-84107-x [pii]
AID - 84107 [pii]
AID - 10.1038/s41598-021-84107-x [doi]
PST - epublish
SO  - Sci Rep. 2021 Feb 25;11(1):4698. doi: 10.1038/s41598-021-84107-x.